Fatty acid synthase (FAS) is a major lipogenic
enzyme catalyzing the synthesis of long-chain
saturated fatty acids. Most breast
cancers require lipogenesis for growth. Here, we demonstrated the effects of
theanaphthoquinone (TNQ), a member of the thearubigins generated by the oxidation of
theaflavin (TF-1), on the expression of FAS in human
breast cancer cells. TNQ was found to suppress the
EGF-induced expression of FAS
mRNA and FAS
protein in MDA-MB-231 cells. Expression of FAS has previously been shown to be regulated by the SREBP family of
transcription factors. In this study, we demonstrated that the
EGF-induced nuclear translocation of SREBP-1 was blocked by TNQ. Moreover, TNQ also modulated
EGF-induced ERK1/2 and Akt phosphorylation. Treatment of MDA-MB-231 cells with
PI 3-kinase inhibitors,
LY294002 and
Wortmannin, inhibited the
EGF-induced expression of FAS and nuclear translocation of SREBP-1. Treatment with TNQ inhibited
EGF-induced EGFR/ErbB-2 phosphorylation and dimerization. Furthermore, treatment with
kinase inhibitors of EGFR and ErbB-2 suggested that EGFR/ErbB-2 activation was involved in
EGF-induced FAS expression. In constitutive FAS expression, TNQ inhibited FAS expression and Akt autophosphorylation in BT-474 cells. The
PI 3-kinase inhibitors and
tyrosine kinase inhibitors of EGFR and ErbB-2 also reduced constitutive FAS expression. In addition, pharmacological blockade of FAS by TNQ decreased cell viability and induced cell death in BT-474 cells. In summary, our findings suggest that TNQ modulates FAS expression by the regulation of EGFR/ErbB-2 pathways and induces cell death in
breast cancer cells.